Cargando…

Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) has long been one of the most prevalent cancers worldwide; even though treatments such as surgery, chemotherapy, radiotherapy and immunotherapy have been proven to benefit the patients and prolong their survival time, the overall five-year survival rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zheng, Yang, Xin, Ainiwaer, Mailudan, Chen, Fei, Liu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821160/
https://www.ncbi.nlm.nih.gov/pubmed/36614974
http://dx.doi.org/10.3390/jcm12010173
_version_ 1784865631339806720
author Jiang, Zheng
Yang, Xin
Ainiwaer, Mailudan
Chen, Fei
Liu, Jun
author_facet Jiang, Zheng
Yang, Xin
Ainiwaer, Mailudan
Chen, Fei
Liu, Jun
author_sort Jiang, Zheng
collection PubMed
description Head and neck squamous cell carcinoma (HNSCC) has long been one of the most prevalent cancers worldwide; even though treatments such as surgery, chemotherapy, radiotherapy and immunotherapy have been proven to benefit the patients and prolong their survival time, the overall five-year survival rate is still below 50%. Hence, the development of new therapies for better patient management is an urgent need. External stimuli-responsive therapies are emerging therapies with promising antitumor effects; therapies such as photodynamic (PDT) and photothermal therapies (PTT) have been tested clinically in late-stage HNSCC patients and have achieved promising outcomes, while the clinical translation of sonodynamic therapy (SDT), radiodynamic therapy (RDT), microwave dynamic/thermodynamic therapy, and magnetothermal/magnetodynamic therapy (MDT/MTT) still lag behind. In terms of preclinical studies, PDT and PTT are also the most extensively studied therapies. The designing of nanoparticles and combinatorial therapies of PDT and PTT can be referenced in designing other stimuli-responsive therapies in order to achieve better antitumor effects as well as less toxicity. In this review, we consolidate the advancements and limitations of various external stimuli-responsive therapies, as well as critically discuss the prospects of this type of therapies in HNSCC treatments.
format Online
Article
Text
id pubmed-9821160
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98211602023-01-07 Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma Jiang, Zheng Yang, Xin Ainiwaer, Mailudan Chen, Fei Liu, Jun J Clin Med Review Head and neck squamous cell carcinoma (HNSCC) has long been one of the most prevalent cancers worldwide; even though treatments such as surgery, chemotherapy, radiotherapy and immunotherapy have been proven to benefit the patients and prolong their survival time, the overall five-year survival rate is still below 50%. Hence, the development of new therapies for better patient management is an urgent need. External stimuli-responsive therapies are emerging therapies with promising antitumor effects; therapies such as photodynamic (PDT) and photothermal therapies (PTT) have been tested clinically in late-stage HNSCC patients and have achieved promising outcomes, while the clinical translation of sonodynamic therapy (SDT), radiodynamic therapy (RDT), microwave dynamic/thermodynamic therapy, and magnetothermal/magnetodynamic therapy (MDT/MTT) still lag behind. In terms of preclinical studies, PDT and PTT are also the most extensively studied therapies. The designing of nanoparticles and combinatorial therapies of PDT and PTT can be referenced in designing other stimuli-responsive therapies in order to achieve better antitumor effects as well as less toxicity. In this review, we consolidate the advancements and limitations of various external stimuli-responsive therapies, as well as critically discuss the prospects of this type of therapies in HNSCC treatments. MDPI 2022-12-26 /pmc/articles/PMC9821160/ /pubmed/36614974 http://dx.doi.org/10.3390/jcm12010173 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jiang, Zheng
Yang, Xin
Ainiwaer, Mailudan
Chen, Fei
Liu, Jun
Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma
title Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma
title_full Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma
title_fullStr Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma
title_full_unstemmed Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma
title_short Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma
title_sort recent clinical and preclinical advances in external stimuli-responsive therapies for head and neck squamous cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821160/
https://www.ncbi.nlm.nih.gov/pubmed/36614974
http://dx.doi.org/10.3390/jcm12010173
work_keys_str_mv AT jiangzheng recentclinicalandpreclinicaladvancesinexternalstimuliresponsivetherapiesforheadandnecksquamouscellcarcinoma
AT yangxin recentclinicalandpreclinicaladvancesinexternalstimuliresponsivetherapiesforheadandnecksquamouscellcarcinoma
AT ainiwaermailudan recentclinicalandpreclinicaladvancesinexternalstimuliresponsivetherapiesforheadandnecksquamouscellcarcinoma
AT chenfei recentclinicalandpreclinicaladvancesinexternalstimuliresponsivetherapiesforheadandnecksquamouscellcarcinoma
AT liujun recentclinicalandpreclinicaladvancesinexternalstimuliresponsivetherapiesforheadandnecksquamouscellcarcinoma